Phibro Animal Health (NASDAQ:PAHC) CEO Jack Bendheim Sells 11,859 Shares

Key Points

• Phibro Animal Health CEO Jack Bendheim sold a total of 11,859 shares for approximately $477,561, reducing his ownership by 16.05%.
• Phibro's stock is currently valued at $42.33, with a market cap of $1.72 billion and a dividend yield of 1.1%, following its recent earnings report that exceeded analyst expectations.
• Institutional investors hold a significant 99.34% of Phibro Animal Health’s stock, indicating strong confidence among hedge funds and large investors in the company.

Phibro Animal Health Corporation (NASDAQ:PAHC - Get Free Report) CEO Jack Bendheim sold 11,859 shares of the stock in a transaction that occurred on Wednesday, October 22nd. The stock was sold at an average price of $40.27, for a total value of $477,561.93. Following the completion of the sale, the chief executive officer directly owned 62,040 shares of the company's stock, valued at approximately $2,498,350.80. This trade represents a 16.05% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Jack Bendheim also recently made the following trade(s):

• On Thursday, October 23rd, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.18, for a total value of $141,433.60.
• On Monday, October 20th, Jack Bendheim sold 16,075 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.38, for a total value of $649,108.50.
• On Friday, October 17th, Jack Bendheim sold 700 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.03, for a total value of $28,021.00.
• On Thursday, September 18th, Jack Bendheim sold 7,022 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.26, for a total value of $282,705.72.
• On Wednesday, September 10th, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The shares were sold at an average price of $41.29, for a total value of $145,340.80.
• On Tuesday, September 9th, Jack Bendheim sold 14,080 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.33, for a total value of $567,846.40.

Phibro Animal Health Stock Performance

NASDAQ:PAHC traded up $1.28 during trading hours on Friday, reaching $42.33. The stock had a trading volume of 295,981 shares, compared to its average volume of 274,171. The company has a debt-to-equity ratio of 2.46, a quick ratio of 1.25 and a current ratio of 2.76. The stock has a 50 day simple moving average of $37.88 and a 200 day simple moving average of $29.06. Phibro Animal Health Corporation has a 12-month low of $16.16 and a 12-month high of $42.80. The stock has a market cap of $1.72 billion, a P/E ratio of 35.87, a price-to-earnings-growth ratio of 1.21 and a beta of 0.83.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last released its earnings results on Wednesday, August 27th. The company reported $0.57 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.52 by $0.05. Phibro Animal Health had a return on equity of 32.14% and a net margin of 3.73%.The business had revenue of $378.70 million during the quarter, compared to the consensus estimate of $362.24 million. Phibro Animal Health has set its FY 2026 guidance at 2.520-2.700 EPS. On average, research analysts forecast that Phibro Animal Health Corporation will post 1.95 EPS for the current fiscal year.

Phibro Animal Health Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, September 24th. Investors of record on Wednesday, September 3rd were paid a dividend of $0.12 per share. The ex-dividend date of this dividend was Wednesday, September 3rd. This represents a $0.48 annualized dividend and a yield of 1.1%. Phibro Animal Health's dividend payout ratio (DPR) is currently 40.68%.

Institutional Investors Weigh In On Phibro Animal Health

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. lifted its stake in shares of Phibro Animal Health by 0.4% in the 1st quarter. Vanguard Group Inc. now owns 1,521,520 shares of the company's stock valued at $32,500,000 after acquiring an additional 6,784 shares during the last quarter. Acadian Asset Management LLC lifted its stake in shares of Phibro Animal Health by 0.5% in the 1st quarter. Acadian Asset Management LLC now owns 782,939 shares of the company's stock valued at $16,713,000 after acquiring an additional 4,144 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Phibro Animal Health by 1.4% in the 2nd quarter. Geode Capital Management LLC now owns 554,927 shares of the company's stock valued at $14,175,000 after acquiring an additional 7,841 shares during the last quarter. Nuveen LLC purchased a new position in Phibro Animal Health during the 1st quarter valued at about $10,312,000. Finally, Invesco Ltd. increased its holdings in Phibro Animal Health by 92.3% during the 1st quarter. Invesco Ltd. now owns 387,739 shares of the company's stock valued at $8,282,000 after purchasing an additional 186,087 shares during the period. Institutional investors own 99.34% of the company's stock.

Analyst Ratings Changes

Several research firms recently issued reports on PAHC. Bank of America lifted their price objective on Phibro Animal Health from $19.00 to $27.00 and gave the company an "underperform" rating in a research note on Friday, August 29th. Morgan Stanley set a $34.00 price objective on Phibro Animal Health in a research note on Thursday, August 28th. Zacks Research raised Phibro Animal Health from a "hold" rating to a "strong-buy" rating in a research note on Monday, September 29th. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Phibro Animal Health in a research note on Tuesday, October 14th. Finally, JPMorgan Chase & Co. raised Phibro Animal Health from a "neutral" rating to an "overweight" rating and lifted their price target for the stock from $25.00 to $35.00 in a research note on Monday, July 7th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, four have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, Phibro Animal Health presently has an average rating of "Hold" and an average price target of $28.40.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.